Enlivex Therapeutics (Nasdaq: ENLV)

Our mission is to establish new equilibriums both in patients immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering AllocetraTM cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the bodys native mechanisms to restore rather than suppress immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated. Highlights: * Advanced clinical-stage...

Enlivex therapeutics (nasdaq: enlv) operates in the Pharmaceutical manufacturing industry.

Enlivex therapeutics (nasdaq: enlv)'s revenue is 11m - 100m

Enlivex therapeutics (nasdaq: enlv) has 11 - 50 employees.